Advanced searches left 3/3

Metastatic Uveal Melanoma - Astrophysics Data System

Summarized by Plex Scholar
Last Updated: 03 November 2021

* If you want to update the article please login/register

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

We report the outcomes of the PEMDAC phase 2 scientific test where the HDAC prevention entinostat was incorporated with the PD-1 prevention pembrolizumab in patients with metastatic uveal melanoma. Goal responses and/or prolonged survival were seen in patients with BAP1 wildtype growths, and in one person with an iris melanoma that showed a UV signature. Longer survival correlated with reduced baseline ctDNA degrees or LDH. To conclude, HDAC restraint and anti-PD1 immunotherapy causes long lasting responses in a part of patients with metastatic.

Source link: https://ui.adsabs.harvard.edu/abs/2021NatCo..12.5155N/abstract

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions